Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Summary

This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the process of stem cell collection in patients with multiple myeloma.

Eligibility

Inclusion Criteria:

* Patient must be able to provide informed consent
* Patients with confirmed diagnosis of multiple myeloma
* Able to swallow and retain oral medication
* All ethnic groups are eligible

Exclusion Criteria:

* Non-English speaking person
* Patients undergoing haploidentical allogeneic hematopoietic stem cell transplant
* Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds
* Any medical complications or conditions that would, in the investigator's judgement, interfere with full participation in the study
* On therapeutic dose of aspirin (doses greater than 81 mg) within 7 days prior to the start of the study

Conditions2

Interventions1

Locations2 sites

Related trials

• Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers — Alexandria University
• Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial — Emory University

Browse More Trials